Tirzepatide Receptor Pharmacology: Imbalanced and Biased Dual GIP/GLP-1 Agonism

RESEARCH · TIRZEPATIDE · RECEPTOR PHARMACOLOGY

Tirzepatide Receptor Pharmacology: Imbalanced and Biased Dual GIP/GLP-1 Agonism

Tirzepatide (LY3298176) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Our earlier articles cover the SURPASS/SURMOUNT programme and body-composition and liver-fat trial readouts. This article stays upstream: how Coskun, Willard and follow-up work describe receptor engagement, signalling bias and the ongoing GIP-receptor agonism-versus-antagonism debate. PurixLab’s Tirzepatide 10mg is a research material for laboratory research use only; clinical trial products and protocols are not the same as a research vial.

Discovery pharmacology: dual agonism by design

Coskun and colleagues characterised LY3298176 as a fatty-acid-modified peptide with dual GIP and GLP-1 receptor agonist activity. In vitro it activated both receptors; in mice it improved glucose tolerance through both receptors and, with chronic administration, decreased body weight and food intake more than a GLP-1 receptor agonist alone. Early human Phase 1 work (142 participants receiving LY3298176, dulaglutide or placebo across single- and multiple-administration cohorts) supported translation of that pharmacology, including fasting-glucose LSM differences versus placebo of −49.12 mg/dL and −43.15 mg/dL in the diabetic proof-of-concept cohorts highlighted in the abstract, and body-weight LSM differences versus placebo reaching −5.09 kg and −4.61 kg in healthy multiple-administration cohorts and −2.62 kg and −2.07 kg in type 2 diabetes cohorts [1]. Those figures describe a regulated investigational product under protocol conditions, not a research-chemical catalogue item.

Imbalance and bias at the two receptors

Willard et al. titled their analysis directly: tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. Occupancy calculations for clinically used exposures implied greater engagement of the GIP receptor than of the GLP-1 receptor. At GIPR, tirzepatide mimicked native GIP; at GLP-1R it showed bias favoring cAMP generation over β-arrestin recruitment, with weaker GLP-1R internalisation than GLP-1. In primary islets, β-arrestin1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, suggesting that GLP-1R bias may support insulin secretion [2]. Cryogenic electron microscopy and molecular-dynamics work later mapped structural determinants of that dual pharmacology: tirzepatide resembles native GIP at GIPR yet differs markedly from GLP-1 at GLP-1R, with less agonist-induced receptor desensitisation, and with fatty-acid modification plus sequence jointly setting the mode of action [3]. Spatiotemporal BRET and imaging comparisons likewise placed tirzepatide (and related dual agonist MAR709) among ligands with preserved maximal cAMP despite partial Gαs recruitment and diminished ligand-induced internalisation relative to native peptides and semaglutide [4].

Does GIPR agonism matter in cells and mice?

Samms et al. showed in obese mice that tirzepatide improved insulin sensitivity beyond GLP-1R agonism alone; in Glp-1r-null mice, where GLP-1R-driven weight loss was absent, tirzepatide still improved insulin sensitivity via enhanced glucose disposal in white adipose tissue, and a long-acting GIPR agonist reproduced that WAT disposal phenotype with linked BCAA/ketoacid reductions [5]. In human islets, El and colleagues found that antagonising GIPR consistently reduced the insulin response to tirzepatide, whereas in mouse islets tirzepatide acted predominantly through GLP-1R because of reduced potency at mouse GIPR — a species mismatch that matters when extrapolating rodent receptor genetics [6]. A 2025 rationale review argues that GIPR activity in islets, CNS (appetite and nausea attenuation) and adipose lipid buffering supports agonism rather than antagonism for metabolic disease [7].

The agonism-versus-antagonism paradox

Both GIPR agonists (as in tirzepatide) and GIPR antagonists (as in some experimental dual strategies) have been reported to enhance weight-loss biology when combined with GLP-1 pathways, which looks paradoxical. Gutgesell et al. showed in male mice that agonism and antagonism lower body weight through different mechanisms: agonism can act in a GLP-1R-independent manner via GABAergic GIPR+ neurons, whereas antagonism’s weight and intake effects required global Gipr or Glp-1r and resembled GLP-1R signalling transcriptionally in the dorsal vagal complex [8]. A head-to-head metabolic comparison in lean and diet-induced obese male mice found that both a GIPR agonist (GIP108) and antagonist (NN-GIPR-Ant) reduced food intake and body weight in obese animals (with unchanged energy expenditure versus pair-fed controls), while GIP108 improved glucose tolerance independently of weight loss and the antagonist reduced insulin sensitivity relative to pair-fed controls [9]. The field therefore still lacks a single settled rule for when agonism or antagonism is preferable.

Open pharmacological questions

  • Human receptor occupancy. Willard’s imbalance argument rests on occupancy methodology for clinical exposures; independent confirmation across tissues is limited [2].
  • Species. Mouse versus human islet GIPR contributions diverge [6].
  • Agonism vs antagonism. Different neural and transcriptional mechanisms can yield similar weight endpoints in mice [8,9].
  • Research material. Structural and signalling papers describe defined peptide preparations; they are not quality claims about PurixLab stock [1,3].

Tirzepatide 10mg at PurixLab

Tirzepatide 10mg: a labelled lyophilized research vial with 10mg per vial, C$129 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/tirzepatide-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View Tirzepatide 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. PubMed 30473097 · PMC6308032 · doi:10.1016/j.molmet.2018.09.009
  2. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):140532. PubMed 32730231 · PMC7526454 · doi:10.1172/jci.insight.140532
  3. Sun B, Willard FS, Feng D, et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc Natl Acad Sci U S A. 2022;119(13):e2116506119. PubMed 35333651 · PMC9060465 · doi:10.1073/pnas.2116506119
  4. Novikoff A, O'Brien SL, Bernecker M, et al. Spatiotemporal GLP-1 and GIP receptor signaling and trafficking/recycling dynamics induced by selected receptor mono- and dual-agonists. Mol Metab. 2021;49:101181. PubMed 33556643 · PMC7921015 · doi:10.1016/j.molmet.2021.101181
  5. Samms RJ, Christe ME, Collins KA, et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. J Clin Invest. 2021;131(12):146353. PubMed 34003802 · PMC8203452 · doi:10.1172/JCI146353
  6. El K, Douros JD, Willard FS, et al. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets. Nat Metab. 2023;5(6):945-954. PubMed 37277609 · PMC10290954 · doi:10.1038/s42255-023-00811-0
  7. Samms RJ, Sloop KW. A Contemporary Rationale for Agonism of the GIP Receptor in the Treatment of Obesity. Diabetes. 2025;74(8):1326-1333. PubMed 40521890 · PMC12278790 · doi:10.2337/dbi24-0026
  8. Gutgesell RM, Khalil A, Liskiewicz A, et al. GIPR agonism and antagonism decrease body weight and food intake via different mechanisms in male mice. Nat Metab. 2025;7(6):1282-1298. PubMed 40301583 · PMC12198009 · doi:10.1038/s42255-025-01294-x
  9. Davies I, Turland A, Tran HD, et al. A metabolic comparison of GIPR agonism versus GIPR antagonism in male mice. Diabetes Obes Metab. 2026;28(2):1160-1167. PubMed 41287212 · PMC12803606 · doi:10.1111/dom.70300

Leave a Comment

Your email address will not be published. Required fields are marked *